Centre Hospitalier William Morey — Clinical Trial Site

24 Registered trials

18 Currently recruiting

Organisation

Centre Hospitalier William Morey

Location

Chalon Sur Saone Cedex, France

Identifier

ORG-100043430

Address

4 Rue Capitaine Drillien, Cs 80120, 71321, France

Departments

Chirurgie digestive et oncologique
Dermatologie
Dermatology
Gastroenterology
Hématologie
HEMATOLOGIE ONCOLOGIE
Hématologie-Oncologie
HGE
ICU
Médecine interne
Medical Oncology
Nephrology
Neurology
Onco-hématologie
Onco-hematology
oncologie
Oncology
Oncology-Hematology
Pôle 1 Cardio Neuro et Diabéto

Clinical trials at this site (24)

Search interface

NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial Recruiting

2024-516780-93-00 Sustained immunosuppression 5 2025-07-09
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting

2024-515118-42-00 Colorectal cancer 11 2024-09-10
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting

2022-501494-39-00 Uncontrolled Hypertension IN patients with moderate to 5 2023-03-28
VAC-WARTS Recruiting

2024-513671-40-00 HPV vaccine 5 2022-06-29
API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P… Recruiting

2024-513191-17-00 autoimmune hemolytic anemia 4 2022-02-03
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in patients with colorectal cancer Ended

2024-515908-39-00 Patients with metastatic colorectal cancer 9 2018-10-29
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
A randomized non-inferiority clinical trial of doxycycline vs BPG for early syphilis Ended

2024-513532-23-00 early syphilis 5 2021-12-06